| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $11K | +0.0% | +5.0% |
| SG&A Expense | $127K | -12.1% | -15.2% |
| Interest Expense | $12K | -0.2% | — |
| Net Income | -$149K | +10.5% | +6.4% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $28K | -51.7% | -64.0% |
| Current Assets | $115K | +16.4% | +45.6% |
| Total Assets | $288K | +22.1% | +203.7% |
| Current Liabilities | $486K | +368.6% | +1677.9% |
| Total Liabilities | $784K | +17.5% | +161.0% |
| Stockholders' Equity | -$496K |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$132K | -44.2% | — |
| Financing Cash Flow | $60K | +20.0% | — |
| -141.3% |